LONDON (Alliance News) - Amryt Pharma PLC said Monday it has received positive results from a pre-clinical study of its potential acromegaly treatment, indicating reduced side effects compared to existing treatments.
Amry said the study of its AP102 drug compound for the potential treatment of acromegaly, a disorder resulting from excess growth hormone, indicated no impairment in glucose control in diabetic rats.
"We are very pleased to report these study results that indicate that our drug compound, AP102, does not impact glucose levels or food or water intake, when administered to diabetic rats. This suggests that it lacks the potential to cause or exacerbate diabetes, which is an issue with some other approved therapies," said Mark Sumeray, chief medical officer of Amryt.
"These positive data results are encouraging and further reinforce our view that AP102 has the potential to improve outcomes for patients suffering from acromegaly, a rare and very distressing disorder which leads to excess growth of the body's tissues over time," added Sumeray.
Amryt said it is progressing AP102 towards clinical trials in 2017.
Shares in Amryt were up 6.5% at 18.10 pence Monday morning.
By Adam Clark; adamclark@alliancenews.com
Copyright 2017 Alliance News Limited. All Rights Reserved.
